肿瘤细胞治疗研究
英文原题：The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma.
弥漫性大B细胞淋巴瘤（DLBCL）可通过标准一线免疫化疗治愈，但近30-40%的患者出现难治或复发。
弥漫性大B细胞淋巴瘤（DLBCL）可通过标准一线免疫化疗治愈，但近30-40%的患者出现难治或复发。几十年来，适合的复发/难治性（R/R）DLBCL患者的标准治疗策略是大剂量化疗后行自体造血干细胞移植（auto-SCT）。然而，挽救治疗失败或不符合后续auto-SCT条件的患者预后极差。目前已开发出多种免疫基础疗法，包括单克隆抗体、抗体药物偶联物、双特异性T细胞衔接抗体、CAR-T 细胞、免疫检查点抑制剂和新型小分子药物。同时，对于具有特定条件的适合患者，异基因SCT和放疗仍是疾病控制所必需的。在本综述中，为扩展临床治疗选择，我们总结了R/R DLBCL患者免疫相关治疗的最新进展，并展望了未来的方向。
Diffuse large B-cell lymphoma (DLBCL) can be cured with standard front-line immunochemotherapy, whereas nearly 30-40% of patients experience refractory or relapse. For several decades, the standard treatment strategy for fit relapsed/refractory (R/R) DLBCL patients has been high-dose chemotherapy followed by autologous hematopoietic stem cell transplant (auto-SCT). However, the patients who failed in salvage treatment or those ineligible for subsequent auto-SCT have dismal outcomes. Several immune-based therapies have been developed, including monoclonal antibodies, antibody-drug conjugates, bispecific T-cell engaging antibodies, chimeric antigen receptor T-cells, immune checkpoint inhibitors, and novel small molecules. Meanwhile, allogeneic SCT and radiotherapy are still necessary for disease control for fit patients with certain conditions. In this review, to expand clinical treatment options, we summarize the recent progress of immune-related therapies and prospect the future indirections in patients with R/R DLBCL.
MEMBER ACCOUNT
登录成功会直接打开下一页。
